Qube Research & Technologies (QRT)
TCRR

Qube Research & Technologies (QRT)’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,431
Closed -$42K – 3162
2022
Q3 		$42K Sell
23,431
-2,749
-11% -$7.97K ﹤0.01% 2175
2022
Q2 		$76K Buy
+26,180
New +$64.6K ﹤0.01% 2031
2021
Q4 		– Sell
-37,785
Closed -$322K – 3115
2021
Q3 		$322K Sell
37,785
-29,345
-44% -$415K ﹤0.01% 1456
2021
Q2 		$1.1M Buy
67,130
+39,592
+144% +$800K 0.01% 898
2021
Q1 		$608K Buy
+27,538
New +$751K 0.01% 1067

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TCRR Position: Q4 2022 in Review

Qube Research & Technologies (QRT) sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 23,431 shares — an estimated $42K sold.

Qube Research & Technologies (QRT) first reported a position in TCRR in Q1 2021 and held it in 5 quarters. The position peaked at $1.1M in Q2 2021. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • Qube Research & Technologies (QRT) reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 23,431 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $42K.
  • Qube Research & Technologies (QRT) first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Qube Research & Technologies (QRT)'s TCR2 Therapeutics Inc. Common Stock position peaked at $1.1M in Q2 2021.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2022, filed 14 Feb 2023.